📖 Approx. 13 min ／ Updated 2026.07.26
Fukuoka Prefecture serves as the economic and medical hub of the Kyushu region, characterized by diverse needs and vibrant business activities within its healthcare industry. In addition to nationwide challenges such as an aging population, uneven distribution of physicians, and the promotion of regional medical care systems, Fukuoka Prefecture also has unique market characteristics. Against this backdrop, mergers and acquisitions (M&A) and business succession for medical corporations are attracting attention as crucial options for building sustainable healthcare delivery systems. This article provides an expert perspective on the trends in medical M&A in Fukuoka Prefecture and the Kyushu area, as well as specific points for achieving success.
Current Status and Background of Medical M&A in Fukuoka Prefecture and the Kyushu Area
The Kyushu region, particularly Fukuoka Prefecture, is experiencing population concentration and an increase in medical institutions. However, some areas also face challenges such as physician shortages and medical deserts. With the “2025 problem” approaching, as the baby boomer generation enters its later years as the elderly, medical demand is expected to increase further. In this context, many medical institutions are grappling with business succession issues, primarily due to a lack of successors. As the age of directors and chairpersons increases, cases where succession within the family becomes difficult are on the rise, leading M&A to emerge as a practical solution for business continuity.
Within Fukuoka Prefecture, there is a mix of areas with a high concentration of clinics and hospitals and intense competition, particularly in urban centers, and areas where the role of core hospitals supporting regional medical care is crucial. M&A trends include acquisitions by medical corporations aiming to expand their service areas, entry into the medical field by other industries, and reorganizations by groups operating multiple clinics. Furthermore, with the advancement of regional medical care systems requiring the reorganization of hospital bed functions and enhanced collaboration, cases where M&A is utilized as a strategic tool are also on the rise. For potential acquirers, medical institutions with stable revenue bases and a track record of community-based medical practice can be attractive investment targets. For sellers, M&A offers the advantage of securing founder profits and planning for retirement while ensuring employee employment and continuous patient care.
Impact of Medical Corporation Types on M&A: Differences Between Those with and Without Equity Contributions
When considering M&A for medical corporations, the type of corporation, specifically whether it has “equity contributions” or not, is an extremely important factor. This is because it significantly impacts the対象 of transfer, valuation methods, and tax treatment, making detailed understanding essential.
Medical Corporations with Equity Contributions
Medical corporations with equity contributions generally grant equity holders the right to claim reimbursement of their contribution upon withdrawal and the right to distribute residual assets upon dissolution, based on the amount they contributed at the time of establishment. In M&A, these equity contributions become the subject of transfer, and their valuation constitutes the capital gains for the equity holders (sellers). Capital gains are typically subject to “separate taxation,” taxed independently from other income. The valuation is often calculated by comprehensively considering methods such as the net asset value method, income capitalization method, and comparable company method. In particular, when holding a significant amount of real estate or high-value medical equipment, their market value assessment becomes important.
Medical Corporations Without Equity Contributions (e.g., Fund Contribution Type)
Conversely, in medical corporations without equity contributions, the funds and assets contributed at the time of establishment are treated as “funds,” and no equity contributions exist. Therefore, there is no right to receive distribution of residual assets upon withdrawal or dissolution. The subject of M&A is the “business itself,” and transactions take the form of changes in directors or business transfers. While there is generally an obligation to return the funds, this return depends on the corporation’s financial status and the provisions of its articles of incorporation. Since there are no equity contributions, issues of capital gains tax to individuals do not arise, but if it is a business transfer of the corporation, corporate tax will be levied on the capital gains.
| Item | Medical Corporation with Equity Contributions | Medical Corporation Without Equity Contributions |
|---|---|---|
| Subject of Transfer | Equity Contributions | Business (Director change, business transfer, etc.) |
| Seller’s Taxation | Capital gains tax on transfer of equity contributions (separate taxation) | No individual taxation in principle (corporate tax in case of corporate business transfer) |
| Complexity of Valuation | Comprehensive evaluation of net asset value, profitability, and future prospects | Evaluation of business future prospects, profitability, brand value, etc. |
| Treatment of Funds | Not applicable | Obligation to return funds (based on articles of incorporation), separate from transfer consideration |
When considering M&A, it is crucial to accurately identify the type of medical corporation targeted and adopt an approach tailored to its specific characteristics. In particular, for medical corporations with equity contributions, conducting advance simulations of the valuation method for equity contributions and capital gains taxation is key to achieving a smooth M&A.
Impact of Medical Fee Revisions, Facility Standards, and Licenses on M&A Valuation
In the M&A of medical institutions, valuation is not solely based on financial status but is also heavily influenced by factors unique to the medical system. Specifically, medical fee revisions, facility standards, and licensing status are directly linked to future profitability and business continuity, making detailed due diligence essential.
Impact of Medical Fee Revisions
Medical fees are revised every two years, and the content directly impacts the management of medical institutions. In M&A valuation, it is necessary to carefully assess how the latest revision has affected the target medical institution’s revenue structure and what impact future revisions are expected to have. For example, changes in fees for specific medical departments or treatments, or revisions to eligibility criteria for additional charges, could necessitate significant adjustments to the post-M&A business plan. Sellers can provide revenue simulations after revisions to reassure buyers.
Compliance with Facility Standards
Medical institutions must meet “facility standards” related to staffing, equipment, and operational methods to claim specific medical fees. In M&A due diligence, a thorough review is conducted to determine whether the target medical institution currently meets the facility standards for the medical fees it claims, whether there have been any past violations, and whether any investment will be required to maintain or improve these standards post-M&A. Non-compliance with facility standards or the costs associated with adapting to future stricter standards can impact the M&A valuation.
Licensing Status
Establishing a medical institution requires various licenses based on laws such as the Medical Practitioners Act, Medical Care Act, and Health Insurance Act. In M&A, it is necessary to confirm that these licenses have been properly obtained and renewed and are being operated without issues within their validity periods. In particular, when merging medical corporations, transferring business, or changing directors, obtaining new licenses or amending existing ones is often required, and the complexity and duration of these procedures must be considered. Whether the institution has received administrative guidance or disciplinary actions in the past, and whether these could affect future operations, are also important checkpoints.
These unique aspects of the medical system present complexities not found in general corporate M&A. To ensure successful M&A, it is crucial to involve professionals well-versed in medical law and healthcare management to appropriately assess these risks and reflect them in the contract terms.
Key Tax and Legal Issues in Medical Corporation M&A
M&A of medical corporations involves numerous unique tax and legal issues that differ from those in typical corporate M&A. Without specialized knowledge in these areas, there is a risk of unexpected troubles and tax burdens.
Treatment of Capital Gains Tax
In M&A involving medical corporations with equity contributions, individual equity holders (sellers) are subject to capital gains tax on the profits from the transfer of their equity contributions. This tax rate is generally a separate tax of approximately 20% (income tax and resident tax combined), but the tax amount can vary significantly depending on the valuation method. Valuation is typically based on methods for unlisted stocks, considering net asset value and comparable company value, but the valuation of medical corporation-specific assets (e.g., medical fee receivables) and the presence of latent gains can affect the tax amount. Buyers may also need to consider the seller’s tax burden in price negotiations.
Treatment of Business Tax
Medical corporations are generally subject to corporate business tax. Changes in business structure or revenue streams before and after M&A can affect the calculation of business tax. In particular, when integrating multiple medical institutions or engaging in new business development, it is important to conduct business tax simulations in advance. Additionally, in the case of a business transfer, it is necessary to check if there are any assets subject to consumption tax (e.g., medical equipment).
Legal Aspects of Shareholder Changes and Fund Repayments
M&A of medical corporations typically involves not only a change of director but also a change of shareholders (similar to shareholders in a stock company). Changes in shareholders may require amendments to the medical corporation’s articles of incorporation and notification to the relevant authorities. For medical corporations without equity contributions, the articles of incorporation often stipulate an obligation to repay funds contributed at the time of establishment, making the treatment of these funds (timing and method of repayment) a key issue in M&A. Fund repayment affects the corporation’s financial status, so buyers must pay particular attention.
Important Tax Considerations in M&A
- ✅ Simulation of capital gains tax for corporations with equity contributions
- ✅ Valuation of medical corporation-specific assets and confirmation of latent gains
- ✅ Existence of assets subject to business tax and consumption tax
- ✅ Conditions for fund repayment and impact on finances
- ✅ Differences in tax burden depending on M&A scheme (stock transfer, business transfer, etc.)
These legal and tax issues are complex, and proceeding without specialized knowledge can lead to subsequent troubles and disadvantages. Collaborating with professionals in each field, such as M&A specialists, tax accountants, and lawyers, and proceeding with their expert advice is the shortcut to success.
M&A Process for Successful Medical M&A in Fukuoka Prefecture
To achieve successful medical M&A in Fukuoka Prefecture, it is necessary to proceed carefully with a deep understanding of the specific circumstances of the medical industry, in addition to the general M&A process. The main steps and points to note at each stage are outlined below.
-
➀
M&A Strategy Formulation and Consultation
Both sellers and buyers clarify their M&A objectives (business succession, business expansion, retirement, etc.) and consult with specialists (M&A intermediaries, tax accountants, lawyers, etc.). A strategy is formulated considering Fukuoka Prefecture’s medical market and regional medical care plans.
-
➁
Evaluation and Matching of Target Medical Institutions
Specialists comprehensively evaluate the target medical institution’s financial status, medical practice records, community contributions, facilities, and personnel to calculate its corporate value. Then, matching is performed with candidate institutions that meet the buyer’s needs.
-
➂
Signing of Letter of Intent (LOI)
If an agreement is reached on the main terms, such as the transfer price and M&A scheme (stock transfer, business transfer, etc.), through negotiations, a Letter of Intent (LOI) is signed. At this stage, terms are confirmed within a non-legally binding scope.
-
➃
Due Diligence (Detailed Investigation)
The buyer conducts a detailed investigation of the target medical institution’s finances, legal affairs, tax matters, human resources, and medical system (medical fee calculation status, facility standards, licenses, medical accident history, etc.). Potential risks are identified at this stage and reflected in the final negotiations.
-
➄
Signing of Final Agreement and Closing
Based on the due diligence findings, the final transfer agreement is signed. Subsequently, payment of consideration, registration changes, and procedures for the succession of licenses are carried out to complete the M&A (closing).
-
➅
Post-Merger Integration (PMI)
Even after M&A, smooth management integration (PMI), including the fusion of organizational cultures, maintaining employee motivation, optimizing medical systems, and integrating IT systems, is key to success. Management that considers contributions to regional medical care is required.
This process needs to be flexibly adjusted based on the situation of the medical corporation and the M&A scheme. Support from M&A advisors with expertise in the medical industry is indispensable for smoothly navigating complex procedures.
Regional Medical Care System Plans in the Kyushu Area and M&A Strategy
Regional medical care system plans are national policies aimed at optimizing the future healthcare delivery system by differentiating and coordinating hospital bed functions and efficiently utilizing medical resources. Each prefecture in the Kyushu area has formulated plans tailored to its regional characteristics, and these plans cannot be ignored when formulating M&A strategies for medical institutions.
Overview of Regional Medical Care System Plans and Kyushu’s Characteristics
Regional medical care system plans aim to optimize the balance of healthcare resources in each region by estimating medical demand and the required number of hospital beds as of 2025 and classifying them into four bed functions: “highly acute care,” “acute care,” “recovery care,” and “chronic care.” In the Kyushu area, while bed reorganization and consolidation are issues in urban areas like Fukuoka Prefecture, maintaining and securing medical institutions is an urgent task in prefectures with depopulated areas. For example, in Fukuoka Prefecture, bed oversupply is pointed out in certain areas, while the regional disparity of physicians and nurses is also a concern. M&A can serve as a means to contribute to achieving the goals of these regional medical care system plans.
Responding to Regional Medical Care System Plans Through M&A
M&A enables strategic responses to the direction indicated by regional medical care system plans in the following ways:
- Reorganization and Differentiation of Bed Functions: Hospitals can contribute to optimizing the overall regional healthcare delivery system by strengthening specific functions through M&A or by collaborating with other hospitals to promote functional differentiation. For instance, an acute care hospital might acquire a hospital with recovery care functions to establish a comprehensive healthcare delivery system.
- Efficient Utilization of Medical Resources: Integration and collaboration among medical institutions allow for the efficient sharing and utilization of human resources such as physicians and nurses, as well as high-cost medical equipment. This is expected to improve healthcare delivery capacity in areas with medical resource shortages.
- Strengthening Medical Collaboration: M&A can serve as an opportunity to enhance collaboration between hospitals and clinics, or between medical institutions with different functions. This contributes to the smooth transition of patients and the establishment of community-based integrated care systems, thereby promoting the regional medical care system plans.
- Resolving Successor Issues and Maintaining Regional Healthcare: By continuing operations through M&A, medical institutions facing closure due to a lack of successors can maintain essential medical services for the region. This holds significant importance, especially for regional medical care system plans in depopulated areas.
When considering M&A in the Kyushu area, a deep understanding of the regional medical care system plans where the target medical institution is located and formulating strategies with an eye on future policy trends are keys to success. M&A that aligns with regional medical care system plans may also receive administrative understanding and lead to smoother procedures.
M&A of medical corporations in Fukuoka Prefecture and the wider Kyushu area involves numerous complex legal, tax, and medical system-specific issues. To appropriately overcome these specialized challenges and achieve optimal M&A for both parties, support from specialists focused on medical M&A is indispensable. At M&A Medical, advisors with deep knowledge and extensive experience in the healthcare industry strongly support your corporation’s M&A and business succession. We also offer free consultations, so please feel free to contact us.
Consultations on Medical Succession to M&A Medical
M&A Medical is a specialized M&A and business succession support service for medical institutions. As an M&A support institution certified by the Small and Medium Enterprise Agency, we support the successful transfer of clinics and medical corporations struggling with a lack of successors, as well as strategic acquisitions, on a success-fee basis.
- Initial consultation and preliminary assessment are free
- No upfront fees or monthly charges (only success fees)
- Strict confidentiality (proceeding under NDA)
- Support available nationwide in all 47 prefectures and for all medical specialties
Please consult with us early, even if you only want to know the market price, have no successor, or are considering joining a group. We are here to help.